Vaccine against streptococcal infections based on recombinant proteins
Inventors
Guss, Bengt • Flock, Jan-Ingmar • Frykberg, Lars • Flock, Margareta
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9333252-B2
Publication Date
2016-05-10
Expiration Date
Abstract
An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.
Core Innovation
The disclosed invention relates to an antigenic composition for antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, comprising a plurality of antigenic components. Each antigenic component includes at least one antigenic epitope, and the composition includes a first fusion polypeptide comprising at least part of a protein designated EAG and at least a part of protein designated CNE, defined by an amino acid sequence as shown in SEQ ID NO: 28, starting from amino acid 12.
The antigenic composition further comprises at least one additional polypeptide selected from specified fusion polypeptides or specified protein portions, including a second fusion polypeptide combining at least part of a protein designated Eq5 and at least a part of protein designated Eq8, and a third fusion polypeptide combining at least part of a protein designated IdeE and at least a part of protein designated Eq5. Further selectable additional components include at least part of proteins designated EndoSe or EndoSz, at least part of proteins designated IdeE or IdeE2, at least part of proteins designated Eq27 or Eq54, and at least part of a protein family designated Scl.
The invention further provides vaccine compositions that include the defined antigenic compositions as an immunizing component, together with a pharmaceutically acceptable carrier, with optional inclusion of an adjuvant. The vaccine compositions are provided in administrable form for intramuscular, intradermal, subcutaneous, or intranasal administration, and are directed to protecting non-human mammals from infection by Streptococcus equi.
Claims Coverage
The independent claims are directed to antigenic compositions with defined fusion polypeptides and specified epitope-containing regions, and to antigenic-composition-based vaccine compositions for protection of non-human mammals. Across the independent claims, two independently defined fusion polypeptide architectures are characterized by specific SEQ ID NO-defined amino acid sequence constraints and by selection of additional antigenic polypeptides containing antigenic epitopes.
EAG-CNE fusion polypeptide with defined sequence constraint
A first fusion polypeptide comprising at least part of a protein designated EAG and at least a part of a protein designated CNE, wherein each said at least part comprises at least one antigenic epitope and wherein the first fusion polypeptide comprises the amino acid sequence as shown in SEQ ID NO: 28, starting from amino acid 12.
Additional polypeptide selection providing epitope-containing components
At least one additional polypeptide selected from a second fusion polypeptide comprising at least part of a protein designated Eq5 and at least a part of a protein designated Eq8; a third fusion polypeptide comprising at least part of a protein designated IdeE and at least a part of a protein designated Eq5; at least part of a protein designated EndoSe or a protein designated EndoSz; at least part of a protein designated IdeE; at least part of a protein designated IdeE2; at least part of a protein designated Eq27; at least part of a protein designated Eq54; and at least part of a protein family designated Scl, wherein each said at least part comprises at least one antigenic epitope.
Eq5-Eq8 fusion polypeptide with defined sequence constraint
A second fusion polypeptide comprising at least part of a protein designated Eq5 and at least a part of a protein designated Eq8, wherein each said at least part comprises at least one antigenic epitope and wherein the second fusion polypeptide comprises the amino acid sequence as shown in SEQ ID NO: 22, starting from amino acid 12.
Vaccine composition with immunizing antigenic composition and pharmaceutically acceptable carrier
A vaccine composition for protecting non-human mammals from infection by Streptococcus equi, comprising the antigenic composition as the immunizing component and a pharmaceutically acceptable carrier.
Adjuvant and administrable routes for vaccine composition
The vaccine composition further includes an adjuvant, and the vaccine composition is provided in an administrable form for intramuscular, intradermal, subcutaneous, or intranasal administration.
The independent claims cover antigenic compositions built around epitope-containing fusion polypeptides defined by specific SEQ ID NO amino acid sequences, including EAG-CNE in SEQ ID NO: 28 starting at amino acid 12 and Eq5-Eq8 in SEQ ID NO: 22 starting at amino acid 12. They further require epitope-containing additional polypeptides selected from designated fusion polypeptides or designated protein portions, and extend the antigenic compositions into vaccine compositions for protection of non-human mammals via inclusion of a pharmaceutically acceptable carrier, optionally with an adjuvant, and for administration by multiple stated routes.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?